Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Urogen Pharma (URGN) had Cash Flow from Financial Activities of $0.03M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$20.25M |
|
$-43.84M |
|
$2.33M |
|
$17.92M |
|
$57.17M |
|
$-36.91M |
|
$-6.54M |
|
$-43.45M |
|
$-43.45M |
|
$-43.84M |
|
$-43.84M |
|
$-43.84M |
|
$-43.84M |
|
$-36.91M |
|
$-37.62M |
|
47.42M |
|
47.42M |
|
$-0.92 |
|
$-0.92 |
|
| Balance Sheet Financials | |
$237.18M |
|
$0.63M |
|
$10.44M |
|
$247.62M |
|
$42.00M |
|
$122.11M |
|
$252.08M |
|
$294.08M |
|
$-46.46M |
|
$-46.46M |
|
$-46.46M |
|
46.10M |
|
| Cash Flow Statement Financials | |
$-42.02M |
|
$-25.96M |
|
|
Cash Flow from Financial Activities |
$0.03M |
$173.06M |
|
$105.11M |
|
$-67.95M |
|
$3.07M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.65 |
|
-- |
|
-- |
|
1.61 |
|
-2.63 |
|
88.50% |
|
-182.26% |
|
-182.26% |
|
-- |
|
-214.53% |
|
-216.47% |
|
$-42.07M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.31 |
|
1.03 |
|
87.26 |
|
94.37% |
|
94.37% |
|
-17.71% |
|
-57.96% |
|
$-1.01 |
|
$-0.89 |
|
$-0.89 |
|